Active immunization of children against diphtheria from epidemiological indications in accordance with the Protective Vaccine Program.
Composition:
1 dose (0.5 ml) contains not less than 30 IU diphtheria toxoid.
Action:
Diphtheria vaccine, adsorbed (on hydrated aluminum hydroxide). The toxoid is obtained by inactivation of the diphtheria toxin from the culture with formaldehydeCorynebacterium diphtheriae. The diphtheria toxoid retains the antigenic properties of the native toxin and is devoid of pathogenicity. It has strong antigenic properties and induces immune system response to produce specific antibodies (seroconversion) and immunological memory. The immunizing properties of the vaccine are enhanced by the adjuvant action of aluminum hydroxide. Appropriate levels of immune antibodies protecting against diphtheria are obtained after all doses have been applied in accordance with the Protective Vaccine Program. The vaccine meets the requirements of the WHO and European Pharmacopoeia established for the diphtheria vaccine.
Contraindications:
Hypersensitivity to the active substance or vaccine excipients (thiomersal). acute infections with fever; mild infections are not a contraindication to administering a vaccine. Chronic diseases during the exacerbation period; vaccination should be carried out after the disease exacerbates. In case of any contraindications to vaccination, the risk of administering the vaccine against the risk of infection should be assessed. Do not give intravascularly.
Precautions:
Vaccination should be preceded by a medical examination and an interview about general health and previous vaccinations and reports of adverse events that could have been caused by them. Provision should be made for immediate treatment in the event of anaphylactic reaction following vaccination. After vaccination, the child should be under the doctor's supervision for 30 minutes. In children undergoing immunosuppressive therapy or immunodeficiency, the response to the vaccine may be reduced - it is recommended to shift the vaccination to completion of therapy and to determine the level of diphtheria antibodies after vaccination. The risk of apnea and the need to monitor respiratory function for 48-72 h should be considered when administering primary immunization doses to very premature premature babies (born ≤ 28 weeks of gestation), especially for children with symptoms of immaturity in the respiratory system. Due to the significant benefits of vaccinating this group of infants, vaccination should not be withheld or deferred. Due to the thiomersal content, the vaccine may cause allergic reactions.
Pregnancy and lactation:
Not applicable. The vaccine is only used in children.
Side effects:
There may be occasional headaches, apnea in very premature premature babies (born ≤ 28 weeks of gestation), elevated body temperature, malaise, reactions at the injection site (redness, painful swelling).
Dosage:
Deep subcutaneously (in the deltoid muscle or the anterior part of the thigh).Basic vaccination - children up to 2 years: two doses of 0.5 ml with an interval of 4-6 weeks, a third dose (0.3 ml) 6-12 months after the second dose; children aged 2-6 years: 2 doses of 0.3 ml with an interval of 4-6 weeks, the third dose (0.3 ml) 6-12 months after the second dose.Revaccination: 0.2 ml dose in children 6 years of age with documented primary vaccination (in the case of the third dose in the second year of life).
(C)
